Levicept Announces the Appointment of James Sandy as Chief Development Officer [Yahoo! Finance]
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: Yahoo! Finance
SANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the appointment of James Sandy as Chief Development Officer (CDO). James brings over 30 years' experience in the pharmaceutical and biotechnology industries covering a wide range of therapeutic areas and development phases I to IV. Most recently he was CDO at F-star Therapeutics where he was responsible for setting the strategy and overseeing the delivery, execution and management of multiple concurrent oncology clinical trials and broader development strategy. Prior to F-star, he held CDO roles at Ellipses Pharma, Immunocore and Creabilis Pharmaceuticals. His earlier career was at AstraZeneca and Pfizer in a variety of senior roles. Over his career, James has taken several drugs to MAA/BLA filing including Celebrex for the treatment of osteoarthritis (OA) pain. Previously a con
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- VectorY Therapeutics Appoints Kevin Pojasek, Ph.D., to Board of DirectorsBusiness Wire
- Immunocore (NASDAQ:IMCR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- Levicept Announces the Appointment of James Sandy as Chief Development OfficerGlobeNewswire
- Assessing Immunocore Holdings (IMCR) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Moderna Refocuses On Rare Diseases As New Leadership Shapes Pipeline [Yahoo! Finance]Yahoo! Finance
IMCR
Earnings
- 11/6/25 - Beat
IMCR
Sec Filings
- 1/30/26 - Form 8-K
- 1/9/26 - Form 8-K
- 12/8/25 - Form 4
- IMCR's page on the SEC website